Incyte agreed on 8 June to acquire Vega Therapeutics from Star Therapeutics for $1.25bn upfront and up to $750m in sales milestones.
Why Incyte Corporation is buying Vega Therapeutics, Inc. (subsidiary of Star Therapeutics)
Incyte said VGA039 is a first-in-class phase 3 asset that could become a growth driver in hematology. It could be the first subcutaneous prophylactic therapy for von Willebrand disease, where current factor replacement often needs two or three intravenous infusions a week.
“VGA039 fits directly into our strategy of building a top-tier growth company for the future”
Deal terms and financing
Incyte buys all shares of Vega under a stock purchase agreement approved by both boards. The deal is an equity acquisition and Incyte expected an R&D charge of about $1.25bn in its third-quarter results.
Regulatory approvals and timing
Closing required Hart-Scott-Rodino clearance. Incyte announced on 6 July 2026 that it had completed the acquisition.
Market context
About 135,000 people in the US have been diagnosed with von Willebrand disease. VGA039 holds FDA Breakthrough Therapy, Fast Track, orphan drug and rare paediatric disease designations.
